trabektedin teva 0,25 mg prašek za koncentrat za raztopino za infundiranje
trabektedin - prašek za koncentrat za raztopino za infundiranje - trabektedin 0,25 mg / 1 viala - trabektedin
trabektedin teva 1 mg prašek za koncentrat za raztopino za infundiranje
trabektedin - prašek za koncentrat za raztopino za infundiranje - trabektedin 1 mg / 1 viala - trabektedin
holoxan 500 mg prašek za raztopino za infundiranje
baxter d.o.o. - ifosfamid - prašek za raztopino za infundiranje - ifosfamid 500 mg / 1 viala - ifosfamid
holoxan 1 g prašek za raztopino za infundiranje
baxter d.o.o. - ifosfamid - prašek za raztopino za infundiranje - ifosfamid 1 g / 1 viala - ifosfamid
holoxan 2 g prašek za raztopino za infundiranje
baxter d.o.o. - ifosfamid - prašek za raztopino za infundiranje - ifosfamid 2 g / 1 viala - ifosfamid
medicinski kisik sol 100 % medicinski plin, stisnjeni
sol s.p.a. - kisik - medicinski plin, stisnjeni - kisik 100 % / 1 jeklenka - kisik
mekinist
novartis europharm limited - trametinib - melanoma - antineoplastična sredstva - melanomatrametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 in 5. trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior braf inhibitor therapy (see section 5. adjuvant treatment of melanomatrametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with stage iii melanoma with a braf v600 mutation, following complete resection. non-small cell lung cancer (nsclc)trametinib v kombinaciji z dabrafenib je indiciran za zdravljenje odraslih bolnikov z napredovalim non-small cell lung cancer z braf v600 mutacija.
bavencio
merck europe b.v. - avelumab - neuroendokrine tumorje - druga zdravila z delovanjem na novotvorbe agenti, monoklonalna protitelesa - zdravilo bavencio je indicirano za samostojno zdravljenje odraslih bolnikov z metastatskim karcinomom merkelove celice (mcc). bavencio v kombinaciji z axitinib je določen za prvo linijo za zdravljenje odraslih bolnikov z napredovalim karcinomom ledvičnih (rkc). bavencio is indicated as monotherapy for the first‑line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc) who are progression-free following platinum‑based chemotherapy.
baycox bovis
kvp pharma veterinär produkte gmbh -
lonquex
teva b.v. - lipegfilgrastim - nevtropenija - immunostimulants, , colony stimulating factors - lonquex is indicated in adults and in children 2 years of age and older for reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).